Anavex Life Sciences Corp (AVXL)

[nidan7500]

WOW,
An excellent example of how all the pieces/work done by/ for AVXL WW (RWE-RWD) using precision systems are for connecting the AD-CNS ( AI SYSTEMS) DOTS . Well done georgejji.

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.arianapharma.com/wp-content/uploads/2019/03/ANAVEX2-73_CTAD_2018_Presentation_v2.pdf

I agree as I have said before I believe that it will be found in the Phase 2b/3 Alzheimer's trial that the APOE e4 allele(s) either one or two will have a higher concentration and therefore better response than APOE e3 or APOE e2 carriers.

As per the Phase 2a Alzheimer's trial:

APOE e4 carriers are 2.4 times more frequent in the High AV2-73 concentration cohort compared to Low concentration cohort



See slides #15, #16 and #17

http://www.arianapharma.com/wp-content/uploads/2019/03/ANAVEX2-73_CTAD_2018_Presentation_v2.pdf

**************************************************

Although on average approximately 25% of the general population in the USA have at least one APOE e4 allele.

Researchers estimate that between 40-65% of people diagnosed with Alzheimer's have the APOE-e4 gene.

https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics#:~:text=Researchers%20estimate%20that%20between%2040,have%20the%20APOE%2De4%20gene.

So on average 52.5% (+/- 12.5%) of those that have been diagnosed with Alzheimer’s disease have the APOE e4 allele in the USA.

BOOOM